Taiwan-developed drug to be tested on severe COVID-19 cases in U.S.
06/04/2021 02:02 PM
Taipei, June 4 (CNA) A drug candidate developed by a Taiwanese company for the treatment of COVID-19 will be administered to seriously ill patients in its Phase II clinical trials in the United States, pending authorization by the relevant authorities, according to the developer Golden Biotechnology Corp.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Four things to know about Bongkrekic acid
03/28/2024 11:27 PM - Society
Tests on deceased in Taipei food poisoning case finds Bongkrekic acid
03/28/2024 11:05 PM - Society
5 people remain in critical condition due to food poisoning in Taipei
03/28/2024 10:13 PM - Culture
Harvard Film Archive to hold event honoring Taiwan director Edward Yang
03/28/2024 09:52 PM - Sports
Turnout for CPBL pre-season games nearly triples
03/28/2024 09:31 PM